

Ionis statement about the Wholesale Acquisition Cost of TRYNGOLZA® (olezarsen)

March 25, 2026 – Effective April 1, Ionis will lower the annual Wholesale Acquisition Cost (WAC) of TRYNGOLZA® (olezarsen)¹ to \$40,000. The new price will apply to the current indication in familial chylomicronemia syndrome (FCS) and will be maintained for the severe hypertriglyceridemia (sHTG) indication across both doses, assuming approval.

As the first and only investigational therapy for sHTG shown to significantly reduce triglycerides and the risk of acute pancreatitis, the price reflects the substantial value that olezarsen can provide to patients, healthcare professionals and the healthcare system, while supporting timely and sustained patient access. Ionis established the new price to align with the [landmark Phase 3 data](#) published in the *New England Journal of Medicine* and expected use by providers, following a thorough review of robust provider research and extensive payer engagement.

Setting the price to address the sHTG population ahead of the FDA action date on June 30 allows for proactive alignment with annual payer contracting cycles for 2027 and strongly positions the company for a seamless launch and accelerating access following approval.

sHTG is defined by very high triglycerides greater than or equal to 500 mg/dL and characterized by an increased risk of potentially life-threatening acute pancreatitis attacks and other serious health complications. Current standard of care therapies for sHTG and lifestyle modifications, such as diet and exercise, do not sufficiently or consistently lower triglyceride levels or reduce the risks of sHTG in all patients. sHTG impacts >3 million people in the U.S., with ~1 million people who are at highest risk.

1. TRYNGOLZA® (olezarsen) is approved as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). Please see [full U.S. Prescribing Information](#).